SACT Pathways, Guidelines for the Management of SACT Induced Adverse Reactions and Nursing 

SACT Pathways 

• For emergency 24 hour telephone advice refer to local Trust policy  
• Bisphosphonate Guidelines for early breast cancer and the prevention of skeletal related events v3
• Extravasation v7
• Guidelines for the Management of SACT Induced Nausea and Vomiting v7
  
• Guidelines for Use of G-CSF in Adult Haematology and Oncology Patients v6
  
• Handling, Administration, Health and Safety v3
  
• Hypercalcaemia Guidelines v4
  
• Intrathecal: refer to local Trust policy
• Guidelines on the Safe Use of Oral Anti-Cancer Medicines v6
  
• Neutropenic sepsis  (Please refer to individual Trust policies for the Antimicrobial Management of Neutropenia) 
  
• Prescribing and Dispensing of SACT v3
• SACT Anaphylaxis v5
  
• SACT Guidelines for the Management of Systemic Anti-Cancer Therapy Induced Diarrhoea Pathway of Care v6
  
• SACT Induced Mucositis & Stomatitis v6
  
• Location of Delivery of Systemic Anti-Cancer Therapy (SACT): refer to local Trust policy         
  
• UK Chemotherapy Board Guidance on DPD testing
  
• KMCC Vascular access guidelines under review to be updated shortly
  

Guidelines for the Management of SACT Induced Adverse Reactions

• Guidelines for Bevacizumab induced hypertension v2   
• Guidelines for Cetuximab induced rashes v4 
• Guidance on the assessment and Management of Oxaliplatin induced Neuropathy v2
• Dose modification schedule & management of adverse reactions to Vemurafenib v1 
  

• Management of Immunotherapy-Related Adverse Events:
  The KMCC Chemotherapy Group have reviewed the St Luke’s Cancer Alliance Guidelines for Management of Immunotherapy-Related Adverse Events and with the kind permission of St Luke’s Cancer Alliance, have agreed to adopt these for use within KMCC.
  
  https://www.royalsurrey.nhs.uk/download.cfm?doc=docm93jijm4n7176.pdf&ver=20133

Nursing 

Palliative Care Guidelines

• Palliative Care Guideline Plus Website

• SOP for reconstitution and administration of romiplostim V1
  

• SOP for the identification and Training of the patient to Self administer of Romiplostim V1

Training and Workforce

• KMCC nurses training documents under review to be updated shortly